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PP-126 Analysis of the virological features and impact on
the efﬁcacy treated with peginterferon alfa-2a
and ribavirin in patients coinfected with HBV and
HCV
Jian-wu Yu*, Li-jie Sun, Yong-hua Zhao, Shu-chen Li. Department
of Infectious Diseases, Second Afﬁliated Hospital, Harbin
Medical University
Objective: To study the virological features and impact on the ef-
ﬁcacy treated with peginterferon alfa-2a and ribavirin in patients
coinfected with HBV and HCV.
Methods: The virological data of 50 patientswere retrospectively
analyzed and virological responses rates treated with peginter-
feron alfa-2a and ribavirin were investigated.
Results: HBV DNA level of patients coinfected with HBV and
HCV (4.6±0.9) log 10 copies/mL was signiﬁcantly lower than
that in HBV monoinfection group (5.9±1.2) log10 copies/mL
(t=5.964, P<0.01). HBeAg positive rate (12.0%, 6/50) of patients
co-infected with HBV and HCV group was signiﬁcantly lower
than that (45.3%,19/42) in HBV monoinfection group (χ2=12.743,
P<0.01). pEVR rate and ETVR rate (50.0%, 15/30; 90.0%, 27/30)
of patients with genotype 1 in HBV and HCV coinfection group
were signiﬁcantly higher than those (16.0%, 4/25; 56.0%, 14/25)
in monoinfection HCV group (χ2=6.971, P=0.008; χ2=8.307,
P=0.004); Relapse rate (55.6%, 15/27) of patients with geno-
type 1 in HBV and HCV coinfection group was signiﬁcantly higher
than that (21.4%, 3/14) in HCV monoinfection group (χ2=4.360,
P=0.037). The incidence of side effects (30%, 15/50) of pa-
tients in HBV and HCV coinfection group was signiﬁcantly higher
than that (13%, 6/46) in HCV monoinfection group (χ2=4.031,
P=0.045). Reactivation rate of HBV DNA (33.3%, 9/27) with HCV
SVR was signiﬁcantly higher than that of patients without SVR
(8.7%, 2/23) (χ2=4.393, P=0.036).
Conclusions: Compared with HCV monoinfected patients, pEVR,
ETVR and relapse rates of patients with genotype 1 in HBV and
HCV coinfection group were high, but they had similar SVR rates.
PP-127 Cloning, expression and identiﬁcation in
immunohistochemistry of humanized single-chain
Fv antibody against hepatitis C virus core protein
Yong-Zhi Lun*,1, Jun Cheng2, Zeng-Guo Yu1, Qi Wang2.
1Department of Pathogenic Biology, Medical College of Dalian
University; 2Institute of Infectious Disease, Beijing Ditan
Hospital
Objective: To clone and express humanized single chain Fv anti-
body (scFv) against hepatitis C virus core protein and identify its
application in immunohistochemistry.
Methods: The phage antibody library was panned by HCV core
protein, which was coated in microtiter plate. After ﬁve rounds
of biopanning, 60 phage clones were identiﬁed speciﬁc to HCV
core protein. The selected scFv was subcloned into the vector
pCANTAB5E for expression as E-tagged soluble scFv. The liver
tissue sections from normal person and patients with chronic
hepatitis C were immunostained.
Results: ELISA and immunohistochemistry study demonstrated
that the human single chain Fv antibody against hepatitis C
virus core protein has a speciﬁc binding character with parafﬁn-
embedded tissues from patients with chronic hepatitis C, but did
not react with liver tissues from healthy persons.
Conclusion: Humanized single chain Fv antibody to HCV core
protein has been identiﬁed by means of the phage display
technology.
PP-128 Metabolic implications of hepatitis C virus
infection & its correlation to steatohepatits in
chronic hepatitis C patients with and without
type 2 diabetes
Maged Refaat*, Howida Mansour, Hanan Farouk,
Mohamed Ghani, Maryam Abdrahman, Afaf Alem. Faculty of
medicine, Ain Shams University
Background: Chronic hepatitis C virus (HCV) infection is not a
simple viral infection; it has many metabolic and autoimmune
complications.
Objective: To investigate the impacts of chronic HCV infection
on glucose & lipid metabolism and its correlation with body mass
index (BMI) and hepatosteatosis in chronic HCV patients.
Patients and methods: (103) chronic HCV patients were involved
in this study, patients were classiﬁed into, Group I: 68 chronic
HCV patients with type 2 diabetes. Group II: 35 chronic HCV
patients without type 2 diabetes. In addition to 25 patients
with type 2 diabetes as controls; group III: calculation of BMI,
measurement of the waist/hip ratio and assessment of fasting
plasma insulin level was done by immune-enzymatic method,
assessment of insulin resistance state by Homeostatic Model
Assessment (HOMA-IR), detection of anti-HCV by 3rd generation
ELISA test & conﬁrmed by qualitative polymerase chain reaction
(PCR).
Results: Diabetic patients with chronic HCV infection have sig-
niﬁcantly higher fasting plasma insulin level, insulin resistance
state, liver enzymes & steatosis/ﬁbrosis scores than non dia-
betic patients,there was non signiﬁcant difference regarding BMI
between all groups. Positive correlations were found between
plasma insulin level, liver enzymes & steatohepatitis in patients
either they were diabetics or not.
Conclusion: Chronic HCV infection may be regarded as an in-
dependent risk factor for the development of type 2 diabetes.
HCV induces a state of insulin resistance which is the key step in
glucose intolerance, virus C induced steatohepatitis and hence
accelerates progression to cirrhosis.
PP-129 HCV genotype distribution in chronic hepatitis C
patients in a tertiary care hospital of Rawalpindi,
Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aims: Genotypes 1-6 have a worldwide distribution.
Types 1a and 1b are predominant in Northern Europe and North
America, and in Southern and Eastern Europe and Japan, respec-
tively. Type 3 in south Asia. Genotype 4 in Egypt, genotype 5 in
Central and South America and genotype 6 is common in China,
Japan and South East Asia. In Pakistan 3a is the commonest
genotype. As reported by different authors HCV genotype 3a
is associated with the most favorable outcome regarding ETR
and SVR after 24 weeks conventional Interferon and Ribavirin
therapy. The aim of this study is to ﬁnd out HCV Genotypes in
newly diagnosed chronic hepatitis C patients.
Methods: This observational study was conducted in chronic
hepatitis C patients treated with conventional interferon 3 MIU
thrice weekly and ribavirin 400 mg bid for 24 weeks. All patients
had raised ALT levels for last 06 months, had positive PCR for
HCV RNA by real time method and liver biopsy was done during
year 2006-2007. Genotyping was done on Roche Genotyping Kit.
Data was analyzed by using SPSS 13.0
Results: Out of 164 patients, 85.9% (n=141) were genotype 3a.
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6.1% (n=10) were genotype 3b. 3.0% (n=5) were genotype 1a. n=
01 had genotype 1b. 4.2% (n= 7) had mixed genotype (3a, 3b/1a,
1b, 3a, 3b).
Conclusion: Majority (85.9%) of chronic hepatitis C patients were
genotype 3a which is associated with favorable outcome after 24
weeks of conventional interferon and ribavirin therapy and only
3.0% had genotype 1a in this cohort.
PP-130 Virological response in relation to biochemical
changes in chronic hepatitis C patients in a
tertiary care hospital in Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background: Alanine aminotransferase is an enzyme produced in
hepatocytes and its raised levels in serum indicate hepatocyte
damage. Furthermore, the number of patients with sustained
viral response (SVR) and with sustained ALT normalization in
non-SVR patients was also signiﬁcantly higher in the combination
therapy versus monotherapy group.
Objectives: To study the effect of Initial ALT levels on predicting
sustained virological response in HCV infected patients getting
conventional Interferon alpha 2b and Ribavirin combination ther-
apy in the Gastroenterology and Hepatology division of Holy
Family Hospital under the National program for prevention and
control of hepatitis in Pakistan.
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=89): Group I: ALT ≤ 45
– n=25; SVR achieved 80.0%, n=20; Relapser 20.0%, n=05
Group II: ALT 45-90
– n=33; SVR achieved 81.8%, n=27; Relapser 18.8%, n=06
Group III: ALT > 90
– n=31; SVR achieved 64.5%, n=20; Relapser 35.5%, n=11
Conclusion: It was concluded that there is signiﬁcant PCR neg-
ativity at 24 weeks in patients with ALT levels upto 90 U/L as
compared to the patients with ALT levels more than 90 U/L.
PP-131 Biochemical Response with interferon alpha 2b
and ribavirin combination therapy in chronic
hepatitis C patients
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aim: Alanine aminotransferase is an enzyme pro-
duced in hepatocytes and its raised levels in serum indicate
hepatocyte damage. Conventional Interferon being an immune
modulator and Ribavirin being a nucleoside analogue antiviral
drug is believed to suppress hepatocyte damage and inﬂamma-
tion and so decrease the levels of ALT in serum of patients with
high ALT levels undergoing combination therapy. The aim is to
study the changes in ALT levels in HCV infected patients get-
ting conventional Interferon alpha 2b and Ribavirin combination
therapy
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=663): At the start of combination therapy the mean
ALT levels were 80.20 with std. deviation of 66.176 and after
06 months of therapy the mean ALT levels were 41.47 with std.
deviation of 42.194. Furthermore, 461 patients had ALT levels
more than 45 before starting combination therapy and out of
these 461 patients 69.6%, n= 321 had normalization of ALT levels
(<45 IU/L).
Conclusion: It was concluded that use of Conventional Interferon
alpha 2b and Ribavirin combination therapy in patients with
chronic Hepatitis C, ALT levels show trend towards Normaliza-
tion.
PP-132 Thrombocytopenia in chronic hepatitis C patients
treated with conventional interferon and
ribavirin in a tertiary care hospital of Rawalpindi,
Pakistan
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background: Thrombocytopenia is one of the major adverse
effects of IFN-α and ribavirin often leading to dose reduction or
treatment discontinuation. Recent data demonstrated that 4-6%
of patients underwent dose modiﬁcation secondary to thrombo-
cytopenia. Reduction of the dose is recommended at 50,000 cell
count/cmm and discontinuation, if the platelet count drops be-
low 30,000 cell/cmm. It is now a known fact that dose reduction
or interruption of therapy leads to lesser SVR.
Methods: This observational study was conducted in chronic
hepatitis C patients treated with conventional interferon 3 MIU
thrice weekly and ribavirin 400 mg bid for 24 weeks. All patients
had raised ALT levels for last 06 months, had positive PCR for
HCV RNA by real time method and liver biopsy was done. Platelet
counts along with hemoglobin concentration and TLC were moni-
tored in all patients on monthly basis. Data was analyzed by using
SPSS 13.0
Results: Out of 422 patients 15% (n=63) developed thrombocy-
topenia at 12 weeks whereas out of the remaining 359 patients
another 6% (n=22) developed thrombocytopenia at 24 weeks of
therapy. 70 Patients had platelet count in the range of 100-
150,000 cells/cmm. 11 patients had platelet count less than
100,000 cells/cmm and 02 patients had platelet count less than
50,000 cells/cmm.
Conclusion: We conclude that thrombocytopenia is present in a
signiﬁcant number of patients receiving conventional interferon
and ribavirin therapy (15% at week 12 and 6% at week 24). 02
patients needed discontinuation of therapy.
PP-133 Correlation of alanine aminotransferase (ALT)
levels with necroinﬂammatory score and stage of
ﬁbrosis on liver biopsy in chronic hepatitis C
patients
Adnan Raja*, Muhammad Umar, Hammamatul Bushra.
Gastroenterology and Hepatology division, Department of
Medicine, Holy Family Hospital, Rawalpindi, Pakistan
Background/Aims: Hepatitis C is the most common cause of
Chronic Liver Disease in Pakistan with HCV prevalence of 4%.
Liver Biopsy is done for suitability of treatment based on necroin-
ﬂammatory score (grade) and stage of ﬁbrosis. The aim of this
study is to evaluate the staging and grading of histological
changes on liver biopsy in Chronic Hepatitis C patients and its
correlation with serum ALT levels.
Methods: Retrospective descriptive study on the patient records
at Gastroenterology and Hepatology division of Holy Family Hos-
pital including patients of Chronic Hepatitis C undergoing ﬁrst
liver biopsy with no prior treatment and excluding those with
other indications for biopsy. Data was analyzed using SPSS 13.
